In February 2005, the Institute consulted on the proposal that its guidance on vinorelbine for the treatment of advanced breast cancer (TAG no.54), its guidance on capecitabine for the treatment of locally advanced or metastatic breast cancer (TAG no.62) and its guidance on trastuzumab for advanced breast cancer (TAG no.34) should be all be updated as part of work on the Institute's upcoming breast cancer guideline.

During consultation, all of the comments received by the Institute agreed with the proposal put forward. 

Therefore, in May 2005, the Institute?s Guidance Executive decided to proceed with the proposal.  

The current guidance will remain in place until the guideline is published, when it will be withdrawn.